Elevation Oncology (ELEV) News Today → Urgent Nvidia Warning (From Altimetry) (Ad) Free ELEV Stock Alerts $3.62 -0.02 (-0.55%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineClariane: First Quarter 2024 Revenuefinance.yahoo.com - April 26 at 8:32 AMElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)seekingalpha.com - April 22 at 2:30 PMElevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 8.2% in Marchmarketbeat.com - April 17 at 11:16 AMBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsmsn.com - April 10 at 2:19 AMPromising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncologymarkets.businessinsider.com - April 9 at 4:19 PMElevation Oncology (NASDAQ:ELEV) Earns Buy Rating from HC Wainwrightmarketbeat.com - April 9 at 8:30 AMElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024finance.yahoo.com - April 8 at 5:40 PMShort Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Expands By 28.3%marketbeat.com - March 30 at 5:36 PMDesign for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist saysmsn.com - March 28 at 6:23 PMMelanoma: All about the risks, symptoms, and common mythsmsn.com - March 28 at 6:23 PMUp 825% So Far in 2024, Can This Penny Stock Go Any Higher?msn.com - March 27 at 1:15 PMAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)markets.businessinsider.com - March 11 at 7:52 AMElevation Oncology Stock (NASDAQ:ELEV), Quotes and News Summarybenzinga.com - March 9 at 5:51 PMAll Three of Our Analysts Agreeinvestorplace.com - March 8 at 8:02 PMElevation Oncology, Inc. to Post Q4 2025 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:ELEV)marketbeat.com - March 8 at 7:22 AMAnalysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)markets.businessinsider.com - March 7 at 11:39 PMElevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023finance.yahoo.com - March 7 at 6:38 PMElevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by JMP Securitiesmarketbeat.com - March 7 at 10:32 AMElevation Oncology, Inc. Q4 Loss decreases, beats estimatesmarkets.businessinsider.com - March 6 at 3:59 PMELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023msn.com - March 6 at 3:59 PMElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024finance.yahoo.com - March 6 at 3:59 PMElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievementsfinance.yahoo.com - March 6 at 3:59 PMTrim the Fat: 3 Overbought Stocks Poised for a Pullbackinvestorplace.com - March 5 at 6:00 PMElevation Oncology, Inc. (NASDAQ:ELEV) Shares Sold by Armistice Capital LLCmarketbeat.com - March 4 at 10:13 AMElevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directorsfinance.yahoo.com - March 4 at 9:40 AMElevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Growth in Short Interestmarketbeat.com - March 4 at 8:20 AMJMP Securities Initiates Coverage of Elevation Oncology (ELEV) with Market Outperform Recommendationmsn.com - March 2 at 2:31 PMOptimistic Buy Rating for Elevation Oncology on EO-3021’s Promising Clinical Advancements and Differentiationmarkets.businessinsider.com - March 1 at 9:49 AMElevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at JMP Securitiesmarketbeat.com - March 1 at 8:27 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firmprnewswire.com - February 29 at 8:00 AMElevation Oncology to Participate in Upcoming Investor Conferencesfinance.yahoo.com - February 28 at 10:06 AMElevation Oncology to Participate in Upcoming Investor Conferencesprnewswire.com - February 28 at 7:30 AMElevation Oncology expands Phase I solid tumour trial to Japanmsn.com - February 24 at 10:57 PMElevation Oncology (ELEV) Price Target Increased by 31.03% to 6.46msn.com - February 24 at 7:55 AM3 Stock Winners That Are Up 400% or More in 2024investorplace.com - February 23 at 9:17 AMElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japanfinance.yahoo.com - February 22 at 8:24 AMElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japanprnewswire.com - February 22 at 7:30 AMElevation Oncology, Inc. (NASDAQ:ELEV) to Post Q1 2024 Earnings of ($0.28) Per Share, HC Wainwright Forecastsmarketbeat.com - February 22 at 7:19 AMStatus Yellow Weather Warning issued for Cork and Kerrymsn.com - February 20 at 10:18 AMHC Wainwright Increases Elevation Oncology (NASDAQ:ELEV) Price Target to $6.00marketbeat.com - February 20 at 8:24 AMEquities Analysts Offer Predictions for Elevation Oncology, Inc.'s Q1 2024 Earnings (NASDAQ:ELEV)marketbeat.com - February 8 at 7:30 AMElevation Oncology, Inc. Forecasted to Earn Q4 2024 Earnings of ($0.27) Per Share (NASDAQ:ELEV)marketbeat.com - February 7 at 8:38 AMElevation Oncology (NASDAQ:ELEV) Trading Up 5.1%marketbeat.com - February 7 at 5:16 AMHow Is The Market Feeling About Elevation Oncology?benzinga.com - January 31 at 4:02 PMElevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Increase in Short Interestmarketbeat.com - January 28 at 10:41 PMElevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directorsfinance.yahoo.com - January 22 at 9:11 AMElevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 20.9% in Decembermarketbeat.com - January 14 at 1:00 PMWith 29% ownership in Elevation Oncology, Inc. (NASDAQ:ELEV), hedge funds investors have a lot riding on the businessfinance.yahoo.com - January 13 at 8:48 AMWhat's Going On With Elevation Oncology Stock?msn.com - January 8 at 6:57 PMElevation Oncology Announces Program Updates and Upcoming 2024 Milestonesfinance.yahoo.com - January 5 at 11:48 AM Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address His win rate puts Warren Buffett to shame… (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss. Click here now for the full story. ELEV Media Mentions By Week ELEV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELEV News Sentiment▼0.020.33▲Average Medical News Sentiment ELEV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELEV Articles This Week▼21▲ELEV Articles Average Week Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMPX News PSTX News XFOR News IPSC News OPT News ADVM News IPHA News ABOS News STRO News CRDF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELEV) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
